
Nicholas Hornstein/X
Feb 25, 2025, 10:33
Nicholas Hornstein: Checkpoint inhibition in dMMR colon cancer is the future
Nicholas Hornstein, Hematologist and Oncologist with Northwell Health, shared an article by Benoit Rousseau, et al. on X:
“Checkpoint inhibition in dMMR colon cancer is the future, but the duration of treatment to elicit optimal response remains unknown.
Dr.Diaz and Cercek of MSK put together a fantastic review and collated about a dozen trials pointing to ~6 months as an optimal time point.
Great weekend read!”
The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers.
Authors: Benoit Rousseau, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 10:35
Feb 25, 2025, 10:33
Feb 25, 2025, 10:26
Feb 25, 2025, 10:20
Feb 25, 2025, 10:15
Feb 25, 2025, 09:44
Feb 25, 2025, 09:44